Search

Your search keyword '"Zeppellini, Annalisa"' showing total 14 results
Start Over Author "Zeppellini, Annalisa"
14 results on '"Zeppellini, Annalisa"'

1. Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations

Author

Incorvaia, Lorena, Monteiro, Fernando Sabino Marques, Massari, Francesco, Park, Se Hoon, Roviello, Giandomenico, Fiala, Ondřej, Myint, Zin W., Kucharz, Jakub, Molina-Cerrillo, Javier, Santini, Daniele, Buttner, Thomas, Poprach, Alexandr, Kopecky, Jindrich, Zeppellini, Annalisa, Pichler, Martin, Buchler, Tomas, Pichler, Renate, Facchini, Gaetano, Fay, Andre Poisl, Soares, Andrey, Manneh, Ray, Iezzi, Laura, Kuronya, Zsofia, Russo, Antonio, Bourlon, Maria T., Bhuva, Dipen, Ansari, Jawaher, Kanesvaran, Ravindran, Grande, Enrique, Buti, Sebastiano, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

2. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Author

Massari, Francesco, Santoni, Matteo, Takeshita, Hideki, Okada, Yohei, Tapia, Jose Carlos, Basso, Umberto, Maruzzo, Marco, Scagliarini, Sarah, Büttner, Thomas, Fornarini, Giuseppe, Myint, Zin W., Galli, Luca, Souza, Vinicius Carrera, Pichler, Renate, De Giorgi, Ugo, Gandur, Nathalia, Lam, Elaine T., Gilbert, Danielle, Popovic, Lazar, Grande, Enrique, Mammone, Giulia, Berardi, Rossana, Crabb, Simon J., Kemp, Robert, Molina-Cerrillo, Javier, Freitas, Marcelo, Luz, Murilo, Iacovelli, Roberto, Calabrò, Fabio, Tural, Deniz, Atzori, Francesco, Küronya, Zsófia, Chiari, Rita, Campos, Saul, Caffo, Orazio, Fay, André P., Kucharz, Jakub, Zucali, Paolo Andrea, Rinck, José Augusto, Zeppellini, Annalisa, Bastos, Diogo Assed, Aurilio, Gaetano, Mota, Augusto, Trindade, Karine, Ortega, Cinzia, Sade, Juan Pablo, Rizzo, Mimma, Fiala, Ondřej, Vau, Nuno, Giannatempo, Patrizia, Barillas, Allan, Monteiro, Fernando Sabino M., Dauster, Breno, Mennitto, Alessia, Nogueira, Lucas, de Carvalho Fernandes, Roni, Seront, Emmanuel, Aceituno, Luís Garcia, Grillone, Francesco, Cutuli, Hernan Javier, Fernandez, Mauricio, Bassanelli, Maria, Kopp, Ray Manneh, Roviello, Giandomenico, Abahssain, Halima, Procopio, Giuseppe, Milella, Michele, Kopecky, Jindrich, Martignetti, Angelo, Messina, Carlo, Caitano, Manuel, Inman, Eva, Kanesvaran, Ravindran, Herchhorn, Daniel, Santini, Daniele, Bamias, Aristotelis, Bisonni, Renato, Mosca, Alessandra, Morelli, Franco, Maluf, Fernando, Soares, Andrey, Nunes, Fernando, Pinto, Alvaro, Zgura, Anca, Incorvaia, Lorena, Ansari, Jawaher, Zabalza, Ignacio Ortego, Landmesser, Johannes, Rizzo, Alessandro, Mollica, Veronica, Marchetti, Andrea, Rosellini, Matteo, Sorgentoni, Giulia, Battelli, Nicola, Buti, Sebastiano, Porta, Camillo, and Bellmunt, Joaquim

Published
2024
Full Text
View/download PDF

3. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Author

Fiala, Ondřej, Buti, Sebastiano, Takeshita, Hideki, Okada, Yohei, Massari, Francesco, Palacios, Georgia Anguera, Dionese, Michele, Scagliarini, Sarah, Büttner, Thomas, Fornarini, Giuseppe, Myint, Zin W., Galli, Luca, Souza, Vinicius Carrera, Pichler, Renate, De Giorgi, Ugo, Quiroga, María Natalia Gandur, Gilbert, Danielle, Popovic, Lazar, Grande, Enrique, Mammone, Giulia, Berardi, Rossana, Crabb, Simon J., Molina-Cerrillo, Javier, Freitas, Marcelo, Luz, Murilo, Iacovelli, Roberto, Calabrò, Fabio, Tural, Deniz, Atzori, Francesco, Küronya, Zsófia, Chiari, Rita, Campos, Saul, Caffo, Orazio, Fay, André P., Kucharz, Jakub, Zucali, Paolo Andrea, Rinck, José Augusto, Zeppellini, Annalisa, Bastos, Diogo Assed, Aurilio, Gaetano, Mota, Augusto, Trindade, Karine, Ortega, Cinzia, Sade, Juan Pablo, Rizzo, Mimma, Vau, Nuno, Giannatempo, Patrizia, Barillas, Allan, Monteiro, Fernando Sabino Marques, Dauster, Breno, Cattrini, Carlo, Nogueira, Lucas, de Carvalho Fernandes, Roni, Seront, Emmanuel, Aceituno, Luís Garcia, Grillone, Francesco, Cutuli, Hernan Javier, Fernandez, Mauricio, Bassanelli, Maria, Roviello, Giandomenico, Abahssain, Halima, Procopio, Giuseppe, Milella, Michele, Kopecky, Jindrich, Martignetti, Angelo, Messina, Carlo, Caitano, Manuel, Inman, Eva, Kanesvaran, Ravindran, Herchenhorn, Daniel, Santini, Daniele, Manneh, Ray, Bisonni, Renato, Zakopoulou, Roubini, Mosca, Alessandra, Morelli, Franco, Maluf, Fernando, Soares, Andrey, Nunes, Fernando, Pinto, Alvaro, Zgura, Anca, Incorvaia, Lorena, Ansari, Jawaher, Zabalza, Ignacio Ortego, Landmesser, Johannes, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Battelli, Nicola, Porta, Camillo, Bellmunt, Joaquim, and Santoni, Matteo

Published
2023
Full Text
View/download PDF

4. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

Author

Santoni, Matteo, Myint, Zin W., Büttner, Thomas, Takeshita, Hideki, Okada, Yohei, Lam, Elaine T., Gilbert, Danielle, Küronya, Zsófia, Tural, Deniz, Pichler, Renate, Grande, Enrique, Crabb, Simon J., Kemp, Robert, Massari, Francesco, Scagliarini, Sarah, Iacovelli, Roberto, Vau, Nuno, Basso, Umberto, Maruzzo, Marco, Molina-Cerrillo, Javier, Galli, Luca, Bamias, Aristotelis, De Giorgi, Ugo, Zucali, Paolo Andrea, Rizzo, Mimma, Seront, Emmanuel, Popovic, Lazar, Caffo, Orazio, Buti, Sebastiano, Kanesvaran, Ravindran, Kopecky, Jindrich, Kucharz, Jakub, Zeppellini, Annalisa, Fiala, Ondřej, Landmesser, Johannes, Ansari, Jawaher, Giannatempo, Patrizia, Rizzo, Alessandro, Zabalza, Ignacio Ortego, Monteiro, Fernando Sabino M., Battelli, Nicola, Calabrò, Fabio, and Porta, Camillo

Published
2023
Full Text
View/download PDF

7. Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study).

Author

Ciccarese, Chiara, Büttner, Thomas, Cerbone, Linda, Zampiva, Ilaria, Monteiro, Fernando Sabino M., Basso, Umberto, Pichler, Martin, Vitale, Maria Giuseppa, Fiala, Ondrej, Roviello, Giandomenico, Kopp, Ray Manneh, Carrozza, Francesco, Pichler, Renate, Grillone, Francesco, Calabuig, Esther Pérez, Zeppellini, Annalisa, Küronya, Zsófia, Galli, Luca, Facchini, Gaetano, and Sunela, Kaisa

Subjects
OVERALL survival, SURVIVAL rate, KINASE inhibitors, IMMUNE response, PROGNOSIS
Abstract

Metastatic renal cell carcinoma (mRCC) carrying sarcomatoid features (sRCC) has aggressive biology and poor prognosis. First‐line immunotherapy (IO)‐based combinations have improved the outcome of clear cell RCC patients, including that of sRCC. Real‐world data confirming the adequate first‐line management of sRCC is largely lacking. We investigated the clinical features and the outcome of sRCC patients treated with IO‐based combinations within the ARON‐1 study population (NCT05287464). The primary objective was to define the incidence and baseline clinical characteristics of sRCC compared with non‐sRCC patients. The secondary objective was to describe the outcome of sRCC patients based on type of first‐line treatment (IO + IO vs. IO + tyrosin kinase inhibitor [TKI]). We identified 1362 mRCC patients with IMDC intermediate or poor risk, 226 sRCC and 1136 non‐sRCC. These two subgroups did not differ in terms of baseline characteristics. The median overall survival (OS) was 26.8 months (95%CI 21.6–44.2) in sRCC and 35.3 months (95%CI 30.2–40.4) in non‐sRCC patients (p =.013). The median progression‐free survival (PFS) was longer in non‐sRCC patients compared to sRCC (14.5 vs. 12.3 months, p =.064). In patients treated with first‐line IO + TKI the median OS was 34.4 months compared to 26.4 months of those who received IO + IO (p =.729). The median PFS was 12.4 months with IO + TKI and 12.3 months with IO + IO (p =.606). In conclusion, we confirm that sRCC are aggressive tumors with poor prognosis. IO‐based combinations improve survival outcomes of sRCC patients, regardless from the type of strategy (IO + IO versus IO + TKI) adopted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Supplementary Data from Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity

Author

Pizzutilo, Elio Gregory, primary, Romanò, Rebecca, primary, Roazzi, Laura, primary, Agostara, Alberto G., primary, Oresti, Sara, primary, Zeppellini, Annalisa, primary, Giannetta, Laura, primary, Cerea, Giulio, primary, Signorelli, Diego, primary, Siena, Salvatore, primary, and Sartore-Bianchi, Andrea, primary

Published
2023
Full Text
View/download PDF

11. Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity

Author

Pizzutilo, Elio Gregory., primary, Romanò, Rebecca, additional, Roazzi, Laura, additional, Agostara, Alberto Giuseppe., additional, Oresti, Sara, additional, Zeppellini, Annalisa, additional, Giannetta, Laura, additional, Cerea, Giulio, additional, Signorelli, Diego, additional, Siena, Salvatore, additional, and Sartore-Bianchi, Andrea, additional

Published
2023
Full Text
View/download PDF

12. Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study

Author

Zeppellini, A, Galimberti, S, Leone, B, Pacifico, C, Riva, F, Cicchiello, F, Capici, S, Maggioni, C, Sala, L, Cazzaniga, M, Zeppellini, Annalisa, Galimberti, Stefania, Leone, Biagio Eugenio, Pacifico, Claudia, Riva, Francesca, Cicchiello, Federica, Capici, Serena, Maggioni, Claudia, Sala, Luca, Cazzaniga, Marina Elena, Zeppellini, A, Galimberti, S, Leone, B, Pacifico, C, Riva, F, Cicchiello, F, Capici, S, Maggioni, C, Sala, L, Cazzaniga, M, Zeppellini, Annalisa, Galimberti, Stefania, Leone, Biagio Eugenio, Pacifico, Claudia, Riva, Francesca, Cicchiello, Federica, Capici, Serena, Maggioni, Claudia, Sala, Luca, and Cazzaniga, Marina Elena

Abstract

BACKGROUND: Tumor microenvironment (TME) is a dynamic setting and changes in TILs and their subpopulations are potential candidates to influence the metastatic process. Aim of this pilot study is to describe the changes occurring between primary breast cancers and their paired metastases in terms of TILs composition. To assess if these changes influence the process of metastasis development, we used a control group of patients.METHODS: We retrospectively identified 18 Luminal patients, for whom primary and metastatic tissue were available (cases) and 18 paired-matched patients (controls), not relapsed after at least 9years of follow-up, and we quantified TILs and their composition (i.e. T CD8+ and CD4+/FOXP3+). The presence of TILs was defined as ≥10%.RESULTS: Our results showed that the microenvironment composition of relapsed patients was poor of TILs (median=5%, I-III quartiles=0.6-5%), CD8+ (2.5%, 0-5%) and CD4+/FOXP3+(0%, 0-0.6%) in the primary tumor. Comparable results were observed in their related metastases (TILs 3.8%, 0.6-5%; CD8+0%, 0-1.3%; CD4+/FOXP3+0%,0-1.9%). On the contrary, the microenvironment in the control group was richer of TILs (5%, 5-17.5%) in comparison to cases, both in primary tumor (p=0.035) and related metastases (p=0.018). Although CD8+ in controls were similar to cases at primary tumor (p=0.6498), but not at metastasis (p=0.0223), they expressed only one part on the TILs subpopulations (p=0.0060), while TILs in the cases at primary tumor were almost completely CD8+ (p=0.5034).CONCLUSIONS: These findings suggest that the lack of activation of immune system in the primary tumor might influence the multifactor process of cancer progression.

Published
2021

14. Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience.

Author

Rizzo M, Morelli F, Ürün Y, Buti S, Park SH, Bourlon MT, Grande E, Massari F, Landmesser J, Poprach A, Takeshita H, Roviello G, Myint ZW, Popovic L, Soares A, Abahssain H, Giannatempo P, Molina-Cerrillo J, Incorvaia L, Salah S, Zeppellini A, Monteiro FSM, Porta C, Gupta S, and Santoni M

Subjects
Humans, Male, Retrospective Studies, Female, Aged, Middle Aged, Aged, 80 and over, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal administration & dosage, Urologic Neoplasms drug therapy, Urologic Neoplasms pathology, Urologic Neoplasms mortality, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell mortality, Carcinoma, Transitional Cell pathology, Adult, Progression-Free Survival, Immune Checkpoint Inhibitors therapeutic use, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use
Abstract

Background: Recently, a plethora of novel systemic agents have been incorporated into the therapeutic armamentarium of advanced urothelial carcinoma (aUC). The antibody-drug conjugate (ADC), enfortumab vedotin (EV), has demonstrated relevant clinical benefit in patients with aUC refractory to platinum and immune-checkpoint inhibitor (ICI) therapy. Our study provides a retrospective, international, real-world analysis comparing the effectiveness of EV to chemotherapy in this setting., Methods: The data were extracted from the medical records of patients treated with EV or chemotherapy following pembrolizumab for recurrent or progressive aUC after platinum-based chemotherapy. Patients were assessed for overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and duration of response (DoR)., Results: Our analysis included 247 patients treated with EV (88, 36%) or chemotherapy (159, 64%). Median OS was 9.1 months (95%CI 7.2-10.7) in the overall study population, 13.6 months (95%CI 10.0-31.0) in patients receiving EV and 6.8 months (95%CI 6.0-8.9) in patients receiving chemotherapy (p < 0.001). The OS benefit of EV was not affected by primary tumour site and histology, metastatic sites, type of first platinum-based chemotherapy or response to pembrolizumab. In the EV cohort, the median PFS was significantly longer (8.8 months [95%CI 6.5-17.0] vs. 3.0 months [95%CI 2.6-3.7]) and the ORR was significantly higher (56% vs. 23%) than in the chemotherapy cohort., Conclusions: The results of our international analysis of real-world data confirm the effectiveness of EV in the sequential strategy of aUC patients who have received prior platinum-based chemotherapy and anti-PD-1 pembrolizumab, regardless of commonly considered prognostic factors., Trial Registration: ClinicalTrials.gov identifier: NCT05290038., (© 2025 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.)

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results